The characteristics of the 6 patients who failed to mount an appropriate IgM and IgG response to pneumococcal vaccination
| Patient . | Age/gender . | Sokal risk score . | TKI . | Duration of TKI therapy (mo) . | Response . | IgM titers (U/mL) . | IgG titers (U/mL) . | IgM memory B-cell frequencies (%) . | Class-switched memory B-cell frequencies (%) . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre . | Post . | Pre . | Post . | ||||||||
| 5 | M/68 | Intermediate | Imatinib | 60 | MMR | 4 | 5 | 23 | 37 | 4.7 | 9.0 |
| 7 | F/38 | Low | Imatinib | 38 | MMR | 23 | 72 | 198 | 270 | 8.1 | 3.2 |
| 8 | F/65 | High | Imatinib | 46 | MMR | 19 | 17 | 176 | 172 | 4.1 | 3.5 |
| 24 | F/42 | Intermediate | Nilotinib | 24 | CCyR | 8 | 30 | 49 | 171 | 4.0 | 11.6 |
| 28 | F/60 | NA | Dasatinib | 17 | CCyR | 14 | 12 | 106 | 110 | 4.5 | 3.8 |
| 29 | F/43 | Low | Dasatinib | 26 | MMR | 14 | 46 | 32 | 170 | 14.9 | 8.8 |
| Patient . | Age/gender . | Sokal risk score . | TKI . | Duration of TKI therapy (mo) . | Response . | IgM titers (U/mL) . | IgG titers (U/mL) . | IgM memory B-cell frequencies (%) . | Class-switched memory B-cell frequencies (%) . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre . | Post . | Pre . | Post . | ||||||||
| 5 | M/68 | Intermediate | Imatinib | 60 | MMR | 4 | 5 | 23 | 37 | 4.7 | 9.0 |
| 7 | F/38 | Low | Imatinib | 38 | MMR | 23 | 72 | 198 | 270 | 8.1 | 3.2 |
| 8 | F/65 | High | Imatinib | 46 | MMR | 19 | 17 | 176 | 172 | 4.1 | 3.5 |
| 24 | F/42 | Intermediate | Nilotinib | 24 | CCyR | 8 | 30 | 49 | 171 | 4.0 | 11.6 |
| 28 | F/60 | NA | Dasatinib | 17 | CCyR | 14 | 12 | 106 | 110 | 4.5 | 3.8 |
| 29 | F/43 | Low | Dasatinib | 26 | MMR | 14 | 46 | 32 | 170 | 14.9 | 8.8 |
MMR, major molecular response; NA, not available.